Health Condition 1: C692- Malignant neoplasm of retina
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Treatment-na ve patients with retinoblastoma who presented for diagnosis and treatment of their condition in 2024. The following are obligatory data in order for a patient to be included in the study: Patient country of residence. Patient sex. Right/left/both eyes involved at time of diagnosis. For the 2027 outcome study, additional data on survival (live/dead) is obligatory. Example of cases to be included in the study (for all examples below, data on country of residence, sex and laterality are obligatory): Patient diagnosed with retinoblastoma during 2024 and received first treatment in 2024. Patient diagnosed with retinoblastoma during 2024 and was not treated at all due to treatment abandonment. Patient that presented to a treatment center during 2024 after receiving initial treatment elsewhere during 2024.If the obligatory data (country of residence, sex and laterality) can be traced and recorded, the patient can be included.
Exclusion criteria
Exclusion criteria: Example of a cases to be excluded from the study: Patient for which data on country of residence and /or sex and /or laterality are missing. A patient diagnosed and treated before 2024 and then came for additional treatment for the same or fellow eye. Patient that presented to a treatment center in 2024 after receiving primary treatment elsewhere before 2024.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the clinical stage at time of diagnosis of treatment-na ve children with Rb who present to treatment centers across the world in 2024. Timepoint: At time of diagnosis | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the treatment outcome of children with Retinoblastoma who were diagnosed in treatment centers across the world in 2024 & followed up for 3 years until 2027Timepoint: At 36 months | — |
Countries
Afghanistan, Albania, Algeria, Angola, Argentina, Armenia, Australia, Austria, Azerbaijan, Bangladesh, Belarus, Belgium, Benin, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Bulgaria, Burkina Faso, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Congo, Costa Rica, Cote d'Ivoire, Croatia, Cuba, Czech Republic, Democratic Republic of the Congo, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Eritrea, Estonia, Ethiopia, Finland, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, India, Indonesia, Iran (Islamic Republic of), Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Kyrgyzstan, Latvia, Lebanon, Liberia, Lithuania, Madagascar, Malawi, Malaysia, Mali, Mexico, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, Norway, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Republic of Korea, Republic of Moldova, Romania, Russian Federation, Rwanda, Saudi Arabia, Senegal, Serbia, Sierra Leone, Singapore, Slovakia, Slovenia, Somalia, South Africa, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Trinidad and Tobago, Tunisia, Turkey, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States of America, Uruguay, Uzbekistan, Venezuela (Bolivarian Republic of), Viet Nam, Zambia, Zimbabwe
Contacts
Public ContactDr Venkata Rama Mohan Gollamudi
Tata Memorial Hospital
Outcome results
None listed